On the other hand, we see an increase in risk-weighted assets up to the crisis, with a slight drop afterwards and the trend steadying since then. The deal will free up capital of some EUR 400 million, primarily by reducing risk-weighted assets by EUR 4.
The Heska Corporation is involved in biotechnical research for the development of vaccines and related diagnostic products for companion animals. The company manufactures health care products for dogs, cats, and horses and markets them to veterinarians.
Kaspersky is considered one of the foremost cybersecurity research firms in the world, and has considerable expertise in designing antivirus software and tools to uncover spyware used by Western intelligence services.